Physiomics PLC Director dealing (1218S)
06 Julio 2020 - 4:00AM
UK Regulatory
TIDMPYC
RNS Number : 1218S
Physiomics PLC
06 July 2020
6 July 2020
Physiomics plc
("Physiomics") or (the "Company")
Director dealing
Physiomics reports that Dr Jim Millen, CEO, has transferred
85,715 ordinary shares of 0.4p each in the capital of the Company
("Ordinary Shares"), acquired during the recently placing,
announced on 27 May 2020, to his account with The Share Centre for
nil consideration, effective 2 July 2020. The beneficial ownership
of the Ordinary Shares remains unchanged and accordingly, Dr Millen
remains interested in 530,356 Ordinary Shares representing
approximately 0.55% of the Company's issued share capital .
PDMR/PCA FCA Transaction Notification
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Jim Millen
-------------------------------- -------------------------------------
2. Reason for the Notification
-----------------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------------- -------------------------------------
b) Initial notification/amendment Initial notification
-------------------------------- -------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name Physiomics plc
-------------------------------- -------------------------------------
b) LEI 213800A71DSZ6ABMTQ91
-------------------------------- -------------------------------------
4. Details of the transaction(s):section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv)each place where transactions have been
conducted
-----------------------------------------------------------------------
a) Description of the Financial Ordinary shares of 0.4p each in the
instrument, type of instrument share capital of the Physiomics plc
-------------------------------- -------------------------------------
Identification code ISIN: GB00BDR6W943
-------------------------------- -------------------------------------
b) Nature of the Transaction Transfer to broking account
-------------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
N/A 85,715
----------
-------------------------------- -------------------------------------
d) Aggregated information N/A - single issuance
Aggregated volume Price
-------------------------------- -------------------------------------
e) Date of the transaction 2 July 2020
-------------------------------- -------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
(XLON)
-------------------------------- -------------------------------------
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0)20 7409 3494
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0)20 3764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC ) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 70 projects, involving over 30 targets and
60 drugs, and has worked with clients such as Merck KGaA, Merck
& Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 120 years collectively of working in
oncology and/or computational biology and over 120 publications in
peer reviewed journals that have attracted thousands of
citations.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHRFMPTMTTMMBM
(END) Dow Jones Newswires
July 06, 2020 05:00 ET (09:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024